FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073978463> ?p ?o ?g. }

• W2073978463 endingPage "1113" @default.
• W2073978463 startingPage "1105" @default.
• W2073978463 abstract "Tadalafil is being investigated for the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH-LUTS). To assess efficacy, including onset, and safety of tadalafil on BPH-LUTS and the subject's and clinician's perception of changes in urinary symptoms. This randomized, double-blind, placebo-controlled, 12-week trial enrolled men ≥45 yr of age with BPH-LUTS for >6 mo, International Prostate Symptom Score (IPSS) ≥13, and maximum urine flow rate (Qmax) ≥4 to ≤15 ml/s. Tadalafil 5 mg (n = 161) or placebo (n = 164), once daily. Analysis of covariance (ANCOVA) modeling evaluated change from baseline in continuous efficacy variables. Categoric efficacy variables were analyzed with the Cochran-Mantel-Haenszel test, and between-group differences in treatment-emergent adverse events (TEAEs) were assessed using the Fisher exact test. Tadalafil significantly improved IPSS results, from baseline to endpoint, compared to placebo (−5.6 vs −3.6; p = 0.004). Reduction in IPSS results was apparent after 1 wk and significant after 4 wk (tadalafil −5.3 vs placebo −3.5; p = 0.003). The BPH Impact Index (BII) was not assessed at week 1; however, BII improvement was apparent at 4 wk (tadalafil −1.8 vs placebo −1.2; p = 0.029) and continued at 12 wk (tadalafil −1.8 vs placebo −1.3; p = 0.057). Tadalafil significantly improved the International Index of Erectile Function–Erectile Function score in sexually active men with erectile dysfunction (ED; 6.7 vs 2.0; p < 0.001) at 12 wk (not assessed at week 1). Few subjects reported one TEAE or more (p = 0.44). For tadalafil, the most common TEAEs were headache (3.7%) and back pain (3.1%). Tadalafil did not significantly improve Qmax or reduce postvoid residual volume. Tadalafil 5 mg once daily for 12 wk resulted in a clinically meaningful reduction in total IPSS results as early as 1 wk and achieved statistical significance at 4 wk in men with BPH-LUTS. The adverse event profile was consistent with that previously reported in men with ED. This clinical trial is registered on the clinicaltrials.gov website (http://www.clinicaltrials.gov). The registration number is NCT00827242." @default.
• W2073978463 created "2016-06-24" @default.
• W2073978463 creator A5027420194 @default.
• W2073978463 creator A5046369646 @default.
• W2073978463 creator A5058021387 @default.
• W2073978463 creator A5069902075 @default.
• W2073978463 creator A5080108966 @default.
• W2073978463 creator A5080243444 @default.
• W2073978463 creator A5088486376 @default.
• W2073978463 creator A5090431664 @default.
• W2073978463 date "2011-11-01" @default.
• W2073978463 modified "2023-10-18" @default.
• W2073978463 title "Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial" @default.
• W2073978463 cites W1590209850 @default.
• W2073978463 cites W1968860914 @default.
• W2073978463 cites W1971833377 @default.
• W2073978463 cites W1975119053 @default.
• W2073978463 cites W1993057480 @default.
• W2073978463 cites W1994414216 @default.
• W2073978463 cites W1995256786 @default.
• W2073978463 cites W2015122735 @default.
• W2073978463 cites W2025969930 @default.
• W2073978463 cites W2026664968 @default.
• W2073978463 cites W2035715829 @default.
• W2073978463 cites W2050093658 @default.
• W2073978463 cites W2051838969 @default.
• W2073978463 cites W2074093603 @default.
• W2073978463 cites W2076357493 @default.
• W2073978463 cites W2078469638 @default.
• W2073978463 cites W2081597080 @default.
• W2073978463 cites W2086240335 @default.
• W2073978463 cites W2087378939 @default.
• W2073978463 cites W2096067652 @default.
• W2073978463 cites W2099702762 @default.
• W2073978463 cites W2109543271 @default.
• W2073978463 cites W2112019723 @default.
• W2073978463 cites W2132697170 @default.
• W2073978463 cites W2169332961 @default.
• W2073978463 cites W2953200146 @default.
• W2073978463 cites W2993539218 @default.
• W2073978463 doi "https://doi.org/10.1016/j.eururo.2011.08.005" @default.
• W2073978463 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21871706" @default.
• W2073978463 hasPublicationYear "2011" @default.
• W2073978463 type Work @default.
• W2073978463 sameAs 2073978463 @default.
• W2073978463 citedByCount "157" @default.
• W2073978463 countsByYear W20739784632012 @default.
• W2073978463 countsByYear W20739784632013 @default.
• W2073978463 countsByYear W20739784632014 @default.
• W2073978463 countsByYear W20739784632015 @default.
• W2073978463 countsByYear W20739784632016 @default.
• W2073978463 countsByYear W20739784632017 @default.
• W2073978463 countsByYear W20739784632018 @default.
• W2073978463 countsByYear W20739784632019 @default.
• W2073978463 countsByYear W20739784632020 @default.
• W2073978463 countsByYear W20739784632021 @default.
• W2073978463 countsByYear W20739784632022 @default.
• W2073978463 countsByYear W20739784632023 @default.
• W2073978463 crossrefType "journal-article" @default.
• W2073978463 hasAuthorship W2073978463A5027420194 @default.
• W2073978463 hasAuthorship W2073978463A5046369646 @default.
• W2073978463 hasAuthorship W2073978463A5058021387 @default.
• W2073978463 hasAuthorship W2073978463A5069902075 @default.
• W2073978463 hasAuthorship W2073978463A5080108966 @default.
• W2073978463 hasAuthorship W2073978463A5080243444 @default.
• W2073978463 hasAuthorship W2073978463A5088486376 @default.
• W2073978463 hasAuthorship W2073978463A5090431664 @default.
• W2073978463 hasConcept C121608353 @default.
• W2073978463 hasConcept C126322002 @default.
• W2073978463 hasConcept C126894567 @default.
• W2073978463 hasConcept C142724271 @default.
• W2073978463 hasConcept C168563851 @default.
• W2073978463 hasConcept C197934379 @default.
• W2073978463 hasConcept C204787440 @default.
• W2073978463 hasConcept C27081682 @default.
• W2073978463 hasConcept C2776235491 @default.
• W2073978463 hasConcept C2776547966 @default.
• W2073978463 hasConcept C2779478474 @default.
• W2073978463 hasConcept C2779929075 @default.
• W2073978463 hasConcept C2780816001 @default.
• W2073978463 hasConcept C71924100 @default.
• W2073978463 hasConceptScore W2073978463C121608353 @default.
• W2073978463 hasConceptScore W2073978463C126322002 @default.
• W2073978463 hasConceptScore W2073978463C126894567 @default.
• W2073978463 hasConceptScore W2073978463C142724271 @default.
• W2073978463 hasConceptScore W2073978463C168563851 @default.
• W2073978463 hasConceptScore W2073978463C197934379 @default.
• W2073978463 hasConceptScore W2073978463C204787440 @default.
• W2073978463 hasConceptScore W2073978463C27081682 @default.
• W2073978463 hasConceptScore W2073978463C2776235491 @default.
• W2073978463 hasConceptScore W2073978463C2776547966 @default.
• W2073978463 hasConceptScore W2073978463C2779478474 @default.
• W2073978463 hasConceptScore W2073978463C2779929075 @default.
• W2073978463 hasConceptScore W2073978463C2780816001 @default.
• W2073978463 hasConceptScore W2073978463C71924100 @default.
• W2073978463 hasIssue "5" @default.
• W2073978463 hasLocation W20739784631 @default.
• W2073978463 hasOpenAccess W2073978463 @default.

• next